Sunovion and PsychoGenics Announce that SEP-363856 Has Received FDA Breakthrough Therapy Designation for the Treatment of People with Schizophrenia
SUMITOMO CHEM UNSP/ADR (SOMMY)
NASDAQ:AMEX Investor Relations:
sumitomo-chem.co.jp/english/ir
Company Research
Source: Business Wire
— SEP-363856 offers an innovative approach to the treatment of schizophrenia including the potential to be the first agent for the treatment of schizophrenia that does not bind to dopamine 2 (D2) receptors — — Schizophrenia affects more than 2 million people in the United States — MARLBOROUGH, Mass. & PARAMUS, N.J.--(BUSINESS WIRE)-- Sunovion Pharmaceuticals Inc. (Sunovion) and PsychoGenics Inc. (PsychoGenics), today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation for SEP-363856, a novel agent for the treatment of people with schizophrenia. Breakthrough Therapy Designation is intended to expedite the development and review of drugs for serious or life-threatening conditions when preliminary clinical evidence indicates that the drug may demonstrate substantial improvement over available therapy on one or more clinically sign
Show less
Read more
Impact Snapshot
Event Time:
SOMMY
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
SOMMY alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
SOMMY alerts
High impacting SUMITOMO CHEM UNSP/ADR news events
Weekly update
A roundup of the hottest topics
SOMMY
News
- China Veterinary Medicine Market Analysis Report 2024-2030, Featuring China Animal Husbandry Industry, Boehringer Ingelheim, Bimeda, Merck, CEVA, Zoetis Services, Virbac and Vetoquinol [Yahoo! Finance]Yahoo! Finance
- Roivant announces $1.5B share buyback, positive Phase 2 data Apr. 02, 2024 9:20 AM ET By: Val Brickates Kennedy , SA News Editor [Seeking Alpha]Seeking Alpha
- Poxel to Report Its 2023 Annual Results by the End of April 2024 [Yahoo! Finance]Yahoo! Finance
- Sumitomo Chemical and Valent BioSciences Announce Divestiture of Pace International and Future Collaboration with AgroFresh Solutions in the Postharvest Solutions Space [Yahoo! Finance]Yahoo! Finance
- Sumitomo Chemical and Valent BioSciences Announce Divestiture of Pace International and Future Collaboration with AgroFresh Solutions in the Postharvest Solutions SpaceBusiness Wire